title: Multiple squamous cell carcinomas following introduction of nilotinib.
abstract: BACKGROUND
  Nilotinib is a second generation tyrosine kinase inhibitor, used in the treatment of chronic myelogenous leukaemia (CML).
  
  
  METHODS
  We assessed a 72-year-old woman who was treated with nilotinib for CML.
  
  
  RESULTS
  During the year following commencement of nilotinib, the patient developed eight squamous cell carcinomas (SCCs) on her legs.
  
  
  CONCLUSIONS
  Development of SCC is a previously unreported adverse reaction to nilotinib.
authors.affiliation: Queensland Institute of Dermatology, Brisbane, QLD, Australia; School of Medicine, University of Queensland, Brisbane, QLD, Australia.
authors.forename: P
authors.initials: P
authors.lastname: Peters
authors.forename: D
authors.initials: D
authors.lastname: Rabbolini
authors.forename: S
authors.initials: S
authors.lastname: Sinnya
authors.forename: K
authors.initials: K
authors.lastname: Khosrotehrani
authors.forename: G
authors.initials: G
authors.lastname: Wagner
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007866:Leg; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects*; D012878:Skin Neoplasms / Q000139:chemically induced*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; C498826:nilotinib